I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for June 25, 2014 meeting (pages 3-8; Tab 1)

IV. Secretary’s report (page 9; Tab 2)

V. Old Business
   A. HMO response to DURB follow-up questions regarding protocols (pages 11-13; Tab 3)
   B. Oxycodone utilization review (page 15; Tab 4)
   C. Low dose quetiapine (Seroquel®) utilization review (pages 17; Tab 5)

VI. New Business
   A. Protocols review (pages 19-24; Tab 6)
      1. Topical lidocaine (Lidoderm®)
      2. Linezolid (Zyvox®)
   B. DURB Annual Report for SFY 2014 – distributed to board members for comments

VII. Informational Highlights/Reports
    2. Summary of DURB Action Items (pages 27-28; Tab 8)
    3. DHS and DHSS Programs Top Drugs Report (pages 29-40; Tab 9)
    4. Medication information: (pages 41-51; Tab 10)
       (a) Study: Emergency Hospitalizations for Unsupervised Prescription Medication Ingestions by Young Children
       (b) Guidance for Pharmacists Dispensing Naloxone – New Jersey office of AG
       (c) Analysis of “Real World” Sovaldi® (sofosbuvir) Use and Discontinuation Rates
       (d) DEA Classifies Tramadol a Controlled Substance
       (e) Study: Psych drug ER trips approach 90,000 a year